168 related articles for article (PubMed ID: 21873160)
1. A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.
Tsujioka H; Fukami T; Yotsumoto F; Ueda T; Hikita S; Takahashi Y; Kondo H; Kuroki M; Miyamoto S
Anticancer Res; 2011 Jul; 31(7):2461-5. PubMed ID: 21873160
[TBL] [Abstract][Full Text] [Related]
2. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
3. The anti-tumor effect of cross-reacting material 197, an inhibitor of heparin-binding EGF-like growth factor, in human resistant ovarian cancer.
Tang XH; Deng S; Li M; Lu MS
Biochem Biophys Res Commun; 2012 Jun; 422(4):676-80. PubMed ID: 22609777
[TBL] [Abstract][Full Text] [Related]
4. Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer.
Yagi H; Yotsumoto F; Sonoda K; Kuroki M; Mekada E; Miyamoto S
Int J Cancer; 2009 Mar; 124(6):1429-39. PubMed ID: 19048624
[TBL] [Abstract][Full Text] [Related]
5. [Reverse of the resistance to paclitaxel of the heparin binding-epidermal growth factor-like growth factor inhibitor in ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2017 Feb; 52(2):110-115. PubMed ID: 28253574
[No Abstract] [Full Text] [Related]
6. Antitumor effects of CRM197, a specific inhibitor of HB-EGF, in T-cell acute lymphoblastic leukemia.
Kunami N; Yotsumoto F; Ishitsuka K; Fukami T; Odawara T; Manabe S; Ishikawa T; Tamura K; Kuroki M; Miyamoto S
Anticancer Res; 2011 Jul; 31(7):2483-8. PubMed ID: 21873163
[TBL] [Abstract][Full Text] [Related]
7. Cross-reacting material 197 reverses the resistance to paclitaxel in paclitaxel-resistant human ovarian cancer.
Tang XH; Deng S; Li M; Lu MS
Tumour Biol; 2016 Apr; 37(4):5521-8. PubMed ID: 26572150
[TBL] [Abstract][Full Text] [Related]
8. Effects of CRM197, a specific inhibitor of HB-EGF, in oral cancer.
Dateoka S; Ohnishi Y; Kakudo K
Med Mol Morphol; 2012 Jun; 45(2):91-7. PubMed ID: 22718294
[TBL] [Abstract][Full Text] [Related]
9. Cross-reacting material 197, a heparin-binding EGF-like growth factor inhibitor, reverses the chemoresistance in human cisplatin-resistant ovarian cancer.
Tang XH; Li M; Deng S; Lu MS
Anticancer Drugs; 2014 Nov; 25(10):1201-10. PubMed ID: 25115341
[TBL] [Abstract][Full Text] [Related]
10. Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy.
Tsujioka H; Yotsumoto F; Hikita S; Ueda T; Kuroki M; Miyamoto S
Curr Opin Obstet Gynecol; 2011 Feb; 23(1):24-30. PubMed ID: 20966750
[TBL] [Abstract][Full Text] [Related]
11. [Role and mechanism of the regulation of nuclear factor-κB by heparin binding-epidermal growth factor-like growth factor in the induction of paclitaxel resistance of ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2019 Apr; 54(4):255-261. PubMed ID: 31006192
[No Abstract] [Full Text] [Related]
12. Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model.
Ishikura N; Yorozu K; Kurasawa M; Yanagisawa M; Sugimoto M; Yamamoto K
Oncol Rep; 2019 Sep; 42(3):1057-1065. PubMed ID: 31322247
[TBL] [Abstract][Full Text] [Related]
13. CRM197 reverses paclitaxel resistance by inhibiting the NAC-1/Gadd45 pathway in paclitaxel-resistant ovarian cancer cells.
Tang XH; Li H; Zheng XS; Lu MS; An Y; Zhang XL
Cancer Med; 2019 Oct; 8(14):6426-6436. PubMed ID: 31490008
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
Rosanò L; Spinella F; Salani D; Di Castro V; Venuti A; Nicotra MR; Natali PG; Bagnato A
Cancer Res; 2003 May; 63(10):2447-53. PubMed ID: 12750265
[TBL] [Abstract][Full Text] [Related]
15. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.
Lu C; Shahzad MM; Moreno-Smith M; Lin YG; Jennings NB; Allen JK; Landen CN; Mangala LS; Armaiz-Pena GN; Schmandt R; Nick AM; Stone RL; Jaffe RB; Coleman RL; Sood AK
Cancer Biol Ther; 2010 Feb; 9(3):176-82. PubMed ID: 20009575
[TBL] [Abstract][Full Text] [Related]
16. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
Previs RA; Armaiz-Pena GN; Ivan C; Dalton HJ; Rupaimoole R; Hansen JM; Lyons Y; Huang J; Haemmerle M; Wagner MJ; Gharpure KM; Nagaraja AS; Filant J; McGuire MH; Noh K; Dorniak PL; Linesch SL; Mangala LS; Pradeep S; Wu SY; Sood AK
J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376174
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of adrenocortical carcinoma by diphtheria toxin mutant CRM197.
Martarelli D; Pompei P; Mazzoni G
Chemotherapy; 2009; 55(6):425-32. PubMed ID: 19996587
[TBL] [Abstract][Full Text] [Related]
18. Pre-clinical study of BK-UM, a novel inhibitor of HB-EGF, for ovarian cancer therapy.
Nam SO; Yotsumoto F; Miyata K; Suzaki Y; Yagi H; Odawara T; Manabe S; Ishikawa T; Kuroki M; Mekada E; Miyamoto S
Anticancer Res; 2014 Aug; 34(8):4615-20. PubMed ID: 25075108
[TBL] [Abstract][Full Text] [Related]
19. HB-EGF inhibition in combination with various anticancer agents enhances its antitumor effects in gastric cancer.
Sanui A; Yotsumoto F; Tsujioka H; Fukami T; Horiuchi S; Shirota K; Yoshizato T; Kawarabayashi T; Kuroki M; Miyamoto S
Anticancer Res; 2010 Aug; 30(8):3143-9. PubMed ID: 20871033
[TBL] [Abstract][Full Text] [Related]
20. Diphtheria toxin mutant CRM197 possesses weak EF2-ADP-ribosyl activity that potentiates its anti-tumorigenic activity.
Kageyama T; Ohishi M; Miyamoto S; Mizushima H; Iwamoto R; Mekada E
J Biochem; 2007 Jul; 142(1):95-104. PubMed ID: 17525101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
